Oncology

A new post hoc analysis of the ADAURA trial highlights the role of osimertinib in detecting molecular residual disease (MRD) in resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer (NSCLC).

Patients recovering from lung cancer surgery may face prolonged hospital stays when wildfires strike, according to new research examining the effects of wildfire disasters on post-operative recovery.

A deep learning model offering a powerful tool for predicting how patients with advanced non-small cell lung cancer (NSCLC) will respond to immune checkpoint inhibitors (ICIs), potentially improving treatment personalization, has been newly developed.

A phase II trial evaluating the combination of pembrolizumab and bevacizumab in patients with untreated melanoma brain metastases (MBM) has demonstrated substantial clinical activity and promising survival outcomes.

In a pivotal development for the oncology community, a recent retrospective study has demonstrated that continuing immunotherapy beyond disease progression offers significant survival benefits for patients with advanced non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).

A recent study reveals a modest increase in early palliative care (PC) billing among Medicare beneficiaries diagnosed with distant-stage cancers from 2010 to 2019.

In Southeastern Michigan, Black men face disproportionately higher mortality rates from prostate cancer, often presenting with more advanced disease stages.

A recent study has revealed that adult survivors of childhood cancer face a significantly elevated risk of developing melanoma, underscoring the necessity for vigilant long-term monitoring and tailored preventive strategies.